Physician profile
Donald Ammerman
NPI 1316032295
$1,516,750.51
in general payments reported to CMS, 2019-2025
21 companies · $412K in 2025
The $412K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $89K · 2021: $130K · 2022: $271K · 2023: $251K · 2024: $280K · 2025: $412K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $845K · Travel and Lodging: $50K · Food and Beverage: $28K · Consulting Fee: $20K · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $844,940.50 |
| Travel and Lodging | $49,973.83 |
| Food and Beverage | $27,929.88 |
| Consulting Fee | $20,075.00 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619,125.43 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $520,937.42 | 2020-2025 | Caplyta |
| Allergan, INC. | $176,573.16 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $165,271.25 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $33,609.09 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $308.74 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $140.13 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $128.28 | 2023-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $124.02 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $85.60 | 2019-2024 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $73.49 | 2019-2020 | |
| Neuronetics, INC. | $72.76 | 2019 | |
| Alkermes, INC. | $56.29 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Avanir Pharmaceuticals, INC. | $41.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.92 | 2021-2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $39.60 | 2024 | |
| Lundbeck LLC | $32.95 | 2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $30.00 | 2019 | |
| Axsome Therapeutics, INC. | $29.86 | 2023 | Sunosi |
| Tris Pharma INC | $15.13 | 2019 | |
| Neos Therapeutics, Lp | $14.95 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Ammerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.